endpts.com·May 4, 2026
Windward Bio has secured $165 million in funding to advance a China-derived drug into Phase 3 trials for asthma, marking a significant step for the Swiss biotech company with its experimental medicines and in-house discovery team.
Windward Bio's successful $165 million funding round to advance a China-derived drug into Phase 3 asthma trials highlights a strategic approach in leveraging international biotech assets for drug development. This indicates a growing trend and potential opportunity in sourcing and advancing promising assets globally, particularly from emerging markets, to diversify and strengthen pipelines in the biotechnology sector.